Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome

Increased circulating soluble P-selectin in polycystic ovary syndrome

“…The only available study in this context reported a reduction of sP-selectin levels by administration of acarbose for 6 months in obese patients with PCOS (28). Recently, it was reported that the soluble endothelial leukocyte adhesion molecule-1 (sE-selectin), which reflects low-grade inflammation of the endothelium (29), is higher in patients with PCOS compared with healthy women (21).…”

Orlistat: current status in clinical therapeutics

“…These medications have also been demonstrated to either be weight neutral or associated with some minimal weight loss in the setting of treatment of diabetes [11][12][13]. Beyond the salutary effects on weight, however, these medications have been shown to have other beneficial effects on cardiovascular risk surrogates and potential in diabetes prevention [14][15][16][17][18]. Extending this paradigm to selective malabsorption of triglycerides, orlistat by inhibiting the action of the major GI lipases causes a fat malabsorption that reduces dietary fat (triglyceride) absorption by~30%.…”

Targets to treat metabolic syndrome in polycystic ovary syndrome

“…There are a few promising studies within the PCOS population, but further research is needed to address conflicting reports on lipid metabolism, insulin, BMI reduction and cardiovascular parameters. [131–135] Orlistat inhibits the hydrolysis of triglycerides and acts as a gastric and pancreatic lipase inhibitor, thereby reducing dietary fat absorption. Orlistat, which has been studied in PCOS-MBS, may hold promise as studies demonstrate reduction of AGEs, which are known to be elevated in PCOS and have associated cardiovascular risk.…”